Lincoln Pharmaceuticals Ltd (LINCOLN) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 294056, "name": "Lincoln Pharma.", "stock_name": "Lincoln Pharma.", "full_name": "Lincoln Pharmaceuticals Ltd", "name_url": "stocks-analysis/lincoln-pharma", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "676.00", "chg": 5.55, "chgp": "0.83%", "dir": 1, "prev_price": "670.45", "mcapval": "1,342.00 Cr", "mcap": "Micro Cap", "scripcode": 531633, "symbol": "LINCOLN", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "India SENSEX", "isin": "INE405C01035", "curr_date": "May 08", "curr_time": "", "bse_nse_vol": "49.66 k", "exc_status": "Active", "traded_date": "May 08, 2026", "traded_date_str": "2026 05 08", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/lincoln-pharma-294056-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "Lincoln Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Indicator Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/lincoln-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-3974666", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/LincolnPharmace_technicaldot_3974666.png", "date": "2026-05-05 08:01:25", "description": "Lincoln Pharmaceuticals Ltd has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish trend as of early May 2026. Despite a slight dip in daily price, key technical indicators present a mixed picture, signalling both opportunities and caution for investors navigating the pharmaceuticals and biotechnology sector." }, { "title": "Lincoln Pharmaceuticals Gains 6.93%: 2 Key Factors Driving the Week’s Momentum", "link": "https://www.marketsmojo.com/news/stocks-in-action/lincoln-pharmaceuticals-gains-693-2-key-factors-driving-the-weeks-momentum-3971891", "imagepath": "", "date": "2026-05-03 11:00:04", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>Apr 27:</strong> Valuation upgrade signals renewed price attractiveness</p>\n <p><strong>Apr 29:</strong> New 52-week high reached at Rs.710.9</p>\n <p><strong>Apr 30:</strong> Profit-taking leads to a 4.19% correction</p>\n <p><strong>May 1:</strong> No trading data available</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.603.55</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.645.40</div><div class=\"stat-change positive\">+6.93..." }, { "title": "Lincoln Pharmaceuticals Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/lincoln-pharmaceuticals-ltd-is-rated-hold-3970099", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/LincolnPharmace_mojoScore_3970099.png", "date": "2026-04-30 10:10:03", "description": "Lincoln Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 March 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 30 April 2026, providing investors with the latest insights into its performance and outlook." }, { "title": "Broad-Based Technical Strength Lifts Lincoln Pharmaceuticals Ltd to 52-Week High of Rs 710.9", "link": "https://www.marketsmojo.com/news/stocks-in-action/lincoln-pharmaceuticals-ltd-hits-new-52-week-high-at-rs7109-3968002", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/LincolnPharmace_priceRelatedfactors_3968002.png", "date": "2026-04-29 10:10:20", "description": "With a decisive surge to Rs 710.9 on 29 Apr 2026, Lincoln Pharmaceuticals Ltd has reached a fresh 52-week high, marking a notable milestone in its price momentum. This rally comes amid a backdrop of strong technical signals and sustained gains over the past three sessions, underscoring the stock's robust upward trajectory." }, { "title": "Lincoln Pharmaceuticals Ltd: Valuation Shifts Signal Renewed Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/lincoln-pharmaceuticals-ltd-valuation-shifts-signal-renewed-price-attractiveness-3963481", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/LincolnPharmace_valuationdot_3963481.png", "date": "2026-04-27 08:00:14", "description": "Lincoln Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, signalling a potential opportunity for investors amid a mixed performance in the Pharmaceuticals & Biotechnology sector. This change is underpinned by improved price-to-earnings and price-to-book value ratios relative to its historical averages and peer group, despite a modest decline in its share price on 27 Apr 2026." }, { "title": "Lincoln Pharmaceuticals Ltd Sees Bullish Momentum Shift Amid Technical Upgrades", "link": "https://www.marketsmojo.com/news/stocks-in-action/lincoln-pharmaceuticals-ltd-sees-bullish-momentum-shift-amid-technical-upgrades-3954897", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/LincolnPharmace_technicaldot_3954897.png", "date": "2026-04-21 08:01:28", "description": "Lincoln Pharmaceuticals Ltd has demonstrated a notable shift in price momentum, supported by a series of bullish technical indicators across multiple timeframes. The stock’s recent upgrade from a Sell to a Hold rating reflects improving market sentiment and technical strength, positioning it favourably within the Pharmaceuticals & Biotechnology sector." }, { "title": "Lincoln Pharmaceuticals Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/lincoln-pharmaceuticals-ltd-is-rated-hold-3953036", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/LincolnPharmace_mojoScore_3953036.png", "date": "2026-04-19 10:10:03", "description": "Lincoln Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 March 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 19 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook." }, { "title": "Lincoln Pharmaceuticals Gains 1.82%: 3 Key Factors Driving the Week", "link": "https://www.marketsmojo.com/news/stocks-in-action/lincoln-pharmaceuticals-gains-182-3-key-factors-driving-the-week-3952805", "imagepath": "", "date": "2026-04-19 10:00:04", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>13 Apr:</strong> Stock edged up slightly to Rs.576.35 despite Sensex decline</p>\n <p><strong>15 Apr:</strong> Strong rally of 2.85% to Rs.592.80 amid Sensex surge</p>\n <p><strong>16 Apr:</strong> Technical and valuation upgrades announced, stock steady at Rs.592.40</p>\n <p><strong>17 Apr:</strong> Mild pullback to Rs.586.60 amid mixed technical signals</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.576.10</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</di..." }, { "title": "Lincoln Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Indicator Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/lincoln-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-3949999", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/LincolnPharmace_technicaldot_3949999.png", "date": "2026-04-17 08:00:44", "description": "Lincoln Pharmaceuticals Ltd has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance as of April 2026. Despite a slight dip in daily price, key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages reveal a complex picture of the stock’s near-term trajectory within the Pharmaceuticals & Biotechnology sector." } ], "total": 972, "sid": "294056", "stock_news_url": "https://www.marketsmojo.com/news/lincoln-pharmaceuticals-294056" }, "announcements": [ { "caption": "Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2", "datetime": "05-May-2026", "details": "<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Lincoln Pharmaceuticals Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24230GJ1995PLC024288</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2025-26 2026-27</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2025-26 2026-27</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>Trusha Shah</td></tr><tr><td>Designation :-</td><td>Company Secretary and Compliance Officer</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>Darshit Shah</td></tr> <tr><td>Designation : -</td><td>Chief Financial Officer</td></tr></table><div> <br/> Date: 05/05/2026<br/><br/></div>", "source": "BSE" }, { "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A", "datetime": "16-Apr-2026", "details": "<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Lincoln Pharmaceuticals Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230GJ1995PLC024288</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: TRUSHA SHAH <br/> Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER <br/> EmailId: TRUSHASHAH@LINCOLNPHARMA.COM</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: DARSHIT SHAH <br/> Designation: CHIEF FINANCIAL OFFICER <br/> EmailId: DARSHIT@LINCOLNPHARMA.COM</div> </div> <div> <br/> Date: 16/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>", "source": "BSE" }, { "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018", "datetime": "06-Apr-2026", "details": "Pursuant to Provision of Regulation 74(5) of SEBI (Depository and Participants) Regulation 2018 We hereby submit the confirmation Certificate received from MUFG Intime India Private Limited Registrar and Share Transfer Agent (RTA) for the Quarter ended March 31 2026.", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Lincoln Pharmaceuticals Ltd has declared <strong>18%</strong> dividend, ex-date: 12 Sep 25", "dt": "2025-09-12", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Lincoln Pharmaceuticals Ltd has announced <strong>10:2</strong> stock split, ex-date: 19 Mar 09", "dt": "2009-03-19", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

Apr 27: Valuation upgrade signals renewed price attractiveness

Apr 29: New 52-week high reached at Rs.710.9

Apr 30: Profit-taking leads to a 4.19% correction

May 1: No trading data available

Read full news article

Lincoln Pharmaceuticals Ltd is Rated Hold

2026-04-30 10:10:03

Lincoln Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 March 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 30 April 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Broad-Based Technical Strength Lifts Lincoln Pharmaceuticals Ltd to 52-Week High of Rs 710.9

2026-04-29 10:10:20

With a decisive surge to Rs 710.9 on 29 Apr 2026, Lincoln Pharmaceuticals Ltd has reached a fresh 52-week high, marking a notable milestone in its price momentum. This rally comes amid a backdrop of strong technical signals and sustained gains over the past three sessions, underscoring the stock's robust upward trajectory.

Read full news article

Lincoln Pharmaceuticals Ltd: Valuation Shifts Signal Renewed Price Attractiveness

2026-04-27 08:00:14

Lincoln Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, signalling a potential opportunity for investors amid a mixed performance in the Pharmaceuticals & Biotechnology sector. This change is underpinned by improved price-to-earnings and price-to-book value ratios relative to its historical averages and peer group, despite a modest decline in its share price on 27 Apr 2026.

Read full news article

Lincoln Pharmaceuticals Ltd Sees Bullish Momentum Shift Amid Technical Upgrades

2026-04-21 08:01:28

Lincoln Pharmaceuticals Ltd has demonstrated a notable shift in price momentum, supported by a series of bullish technical indicators across multiple timeframes. The stock’s recent upgrade from a Sell to a Hold rating reflects improving market sentiment and technical strength, positioning it favourably within the Pharmaceuticals & Biotechnology sector.

Read full news article

Lincoln Pharmaceuticals Ltd is Rated Hold

2026-04-19 10:10:03

Lincoln Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 March 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 19 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Lincoln Pharmaceuticals Gains 1.82%: 3 Key Factors Driving the Week

2026-04-19 10:00:04

Key Events This Week

13 Apr: Stock edged up slightly to Rs.576.35 despite Sensex decline

15 Apr: Strong rally of 2.85% to Rs.592.80 amid Sensex surge

16 Apr: Technical and valuation upgrades announced, stock steady at Rs.592.40

17 Apr: Mild pullback to Rs.586.60 amid mixed technical signals

Week Open

Rs.576.10

Week CloseRead full news article

Lincoln Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Indicator Signals

2026-04-17 08:00:44

Lincoln Pharmaceuticals Ltd has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance as of April 2026. Despite a slight dip in daily price, key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages reveal a complex picture of the stock’s near-term trajectory within the Pharmaceuticals & Biotechnology sector.

Read full news article

View All News

Sr. No.	Particulars	Details
1	Name of Company	Lincoln Pharmaceuticals Ltd
2	CIN NO.	L24230GJ1995PLC024288
3	Report filed for FY	2025-2026
Details of the Current block (all figures in Rs crore):
4	2 - year block period (Specify financial years)*	2025-26 2026-27
5	Incremental borrowing done in FY (T)(a)	0.00
6	Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)	0.00
7	Actual borrowing done through debt securities in FY (T)(c)	0.00
8	Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)	0
8	Quantum of (d) which has been met from (c)(e)*	0
9	Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*	0

Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):
2 - year Block period (Specify financial years)	2025-26 2026-27
Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#	0.00

Name of the Company Secretary :-	Trusha Shah
Designation :-	Company Secretary and Compliance Officer
Name of the Chief Financial Officer :-	Darshit Shah
Designation : -	Chief Financial Officer